A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
Overview
Lewy body spectrum disorders are a common group of neurodegenerative diseases that cause memory loss, behavioural and motor disabilities that impair quality of life. Cognitive enhancers help people afflicted with these conditions. However, some people do not benefit from this treatment, while others experience serious side effects. Side effects and poor response lead to hospitalization and early institutionalization. Pharmacogenomics, the study of how DNA variation can influence drug effects, will be combined with functional changes in brain imaging in response to cognitive enhancers in patients with Lewy body disease. The goal is to develop a predictive test that can be administered in the clinic to aid physicians' choice of initial medication. This can reduce health care costs and improve treatment to Canadians suffering from these devastating disorders.
Full Title of Study: “Lewy Body Spectrum Disorders: Investigating Neuropsychiatric Benefit and Adverse Effects in Response to Cholinesterase Inhibitors Using Genetics and Brain SPECT”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: January 2016
Interventions
- Drug: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
Arms, Groups and Cohorts
- Parkinson’s Disease Dementia
- Participants in the Parkinson’s Disease Dementia group: Must be taking a stable parkinsonian medication Must have a diagnosis of clinically definite Parkinson’s disease >1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents. Response to cholinesterase inhibitor over a period of six months will be monitored.
- Dementia with Lewy Bodies
- Participants in the Dementia with Lewy Bodies group: Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism. Response to cholinesterase inhibitor over a period of six months will be monitored.
Clinical Trial Outcome Measures
Primary Measures
- Change from baseline in perfusion brain SPECT at 6 months
- Time Frame: 0 and 6 months
- Change from baseline in neuropsychological assessment scores at 6 months
- Time Frame: 0 and 6 months
Secondary Measures
- Volumetric Brain MRI
- Time Frame: Baseline
Participating in This Clinical Trial
Inclusion Criteria
Inclusion criteria for patients with a Lewy body spectrum disorder includes: age > 50 years; and mild-moderate dementia (Mini-Mental State Exam [MMSE] > 9); contact on at least four of seven days/week with a responsible caregiver; Hoehn & Yahr stage ≤ 4. Exclusion Criteria:
- age < 50; Severe dementia (MMSE < 9); contact < 4 days a week with a responsible caregiver; Hoehn & Yahr stage > 4.
Gender Eligibility: All
Minimum Age: 50 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Provider of Information About this Clinical Study
- Principal Investigator: Dr. Mario Masellis, Clinician-Scientist – Sunnybrook Health Sciences Centre
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.